Literature DB >> 15314258

EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.

Vered Lavie1, Maria Becker, Rachel Cohen-Kupiec, Iftach Yacoby, Rela Koppel, Manuela Wedenig, Birgit Hutter-Paier, Beka Solomon.   

Abstract

We have developed an immunization procedure for the production of effective anti-beta-amyloid (anti-Abeta) antibodies, using filamentous phage displaying only 4 amino acids. The EFRH sequence, encompassing amino acids 3-6 of the 42 residues of Abeta peptide, was found previously to be the main regulatory site for amyloid modulation and the epitope of anti-aggregating antibodies. Engineered filamentous phage enable the display of various numbers of EFRH copies on the phage and serve as potent carriers of antigens. In the present study we have found that phage displaying high EFRH copy number are effective in eliciting humoral response against the EFRH sequence, which in turn relieves the amyloid burden in the brains of amyloid precursor protein Tg mice and improves their ability to perform cognitive tasks. Copyright 2004 Humana Press Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15314258     DOI: 10.1385/JMN:24:1:105

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  13 in total

1.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Authors:  H L Weiner; C A Lemere; R Maron; E T Spooner; T J Grenfell; C Mori; S Issazadeh; W W Hancock; D J Selkoe
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

3.  Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.

Authors:  D Frenkel; O Katz; B Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

4.  Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.

Authors:  Frédérique Bard; Robin Barbour; Catherine Cannon; Robert Carretto; Michael Fox; Dora Games; Teresa Guido; Kathleen Hoenow; Kang Hu; Kelly Johnson-Wood; Karen Khan; Dora Kholodenko; Celeste Lee; Mike Lee; Ruth Motter; Minh Nguyen; Amanda Reed; Dale Schenk; Pearl Tang; Nicki Vasquez; Peter Seubert; Ted Yednock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-03       Impact factor: 11.205

5.  Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.

Authors:  Dan Frenkel; Ilse Dewachter; Fred Van Leuven; Beka Solomon
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641

6.  N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.

Authors:  D Frenkel; M Balass; B Solomon
Journal:  J Neuroimmunol       Date:  1998-08-01       Impact factor: 3.478

7.  Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

Authors:  B Solomon; R Koppel; D Frankel; E Hanan-Aharon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

8.  Generation of auto-antibodies towards Alzheimer's disease vaccination.

Authors:  D Frenkel; N Kariv; B Solomon
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

9.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

10.  Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.

Authors:  B Solomon; R Koppel; E Hanan; T Katzav
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

View more
  22 in total

1.  Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model.

Authors:  Ning Cheng; Li Bai; Elizabeth Steuer; Leonardo Belluscio
Journal:  J Neurosci       Date:  2013-07-24       Impact factor: 6.167

Review 3.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

4.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

5.  Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.

Authors:  Rinaldo Zurbriggen; Mario Amacker; Andreas R Kammer; Nicole Westerfeld; Peter Borghgraef; Fred Van Leuven; Ingrid Van der Auwera; Stefaan Wera
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

6.  Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease.

Authors:  Maria Becker; Vered Lavie; Beka Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

Review 7.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 8.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

9.  Molecular basis for passive immunotherapy of Alzheimer's disease.

Authors:  Anna S Gardberg; Lezlee T Dice; Susan Ou; Rebecca L Rich; Elizabeth Helmbrecht; Jan Ko; Ronald Wetzel; David G Myszka; Paul H Patterson; Chris Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

Review 10.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.